ACC/AHA Issue Report for CV and Non-CV Complications of COVID-19

June 30, 2022

The American College of Cardiology/American Heart Association ​​Task Force on Clinical Data Standards published a report June 23 listing and defining key data elements related to cardiovascular and noncardiovascular complications of COVID-19. 

The TL;DR on the ABIM LKA

June 1, 2022

Instead of sitting for the traditional 10-year MOC exam, LKA participants choose when and where to answer assessment questions, find out in real-time if they were right or wrong, and receive a rationale and references to provide context and enhance learning. 

Focus on K2P Faculty: Dr. Michelle Kittleson

May 19, 2022

The world of advanced heart failure is relatively small and specialized, but the most important thing learners should know is when to identify a patient who's heading down that slippery slope of advanced heart failure.

Focus on K2P Faculty: Dr. George Bakris

May 12, 2022

Dr. Bakris has been extensively involved as either a principal investigator or on the steering committees of national and international trials involving diabetic kidney disease progression and resistant hypertension. There are many people with different types of hypertension, isolated, systolic, masked, and white coat hypertension. Continue reading...

ACC 2022: Update on Mavacamten for Obstructive Hypertrophic Cardiomyopathy

April 29, 2022

Mavacamten had a big week at the American College of Cardiology 2022 Scientific Sessions, with two positive Late-Breaking Clinical Trial sessions.  Mavacamten is an investigational, ​first-in-class, cardiac-specific myosin inhibitor that reduces the number of available actin-myosin cross-bridges and thus decreases excessive myocardial contractility.

Focus on K2P Faculty: Dr. Neil Stone

April 12, 2022

Dr. Neil Stone serves as faculty for K2P’s LEGENDS series, where he has provided a talk on the prevention of cardiovascular disease through lipid management.

ACC 2022: Novel Gene-Silencing Therapy Cuts Lp(a) by 98%

April 11, 2022

Among the top-notch research presented at the American College of Cardiology 2022 Scientific Sessions was a small phase 1 trial that demonstrated big potential for a therapeutic that will lower lipoprotein [Lp(a)] and reduce atherosclerotic risk. 

Electrophysiology Legend Dr. Hugh Calkins Interview

April 4, 2022

Dr. Hugh Calkins is a member of the K2P Legends Series faculty and has provided a video entitled “Electrophysiology: State of the Science.” 

Coronary Artery Disease Legend Dr. Deepak Bhatt Interview

April 4, 2022

Dr. Deepak Bhatt serves as faculty for K2P’s LEGENDS series, where he has provided a retrospective on coronary artery disease. He also contributes regularly to other K2P activities, providing education and an expert perspective to many of our programs. 

Q&A with Dr. Ty Gluckman – CurrentMD Cardiology

March 31, 2022

Dr. Ty Gluckman is the Curriculum Chair for K2P’s CurrentMD™ Cardiology product, where he helps to strategize and oversee the cardiology curriculum. He also contributes regular content on a variety of topics, including evaluation of chest pain and risk factor assessment.

ACC Issues Guidance on Cardiovascular Sequelae of COVID-19

March 29, 2022

The American College of Cardiology has released a new Expert Consensus Decision Pathway (ECDP) to address the evaluation and management of some of the more common post-COVID cardiovascular consequences. The effort was co-chaired by Ty Gluckman, MD, MHA, FACC, and Nicole M. Bhave, MD, FACC.

FDA Approves Empagliflozin for HFpEF

March 3, 2022

FDA Approves Empagliflozin for Heart Failure with Preserved Ejection Fraction. With this latest FDA approval, it’s time to get up to date on the newest treatments for heart failure. K2P is here to help.

2 of 9